CompletedPhase 2

Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH

South Korea87 participantsStarted 2023-02-15

Plain-language summary

The study aims to evaluate the safety of J2H-1702 compared to the placebo and explore the efficacy of J2H-1702 at Week 12 timepoint after administration compared to baseline in patients with NASH.

Who can participate

Age range

19 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. A subject aged ≥19 years to ≤75 years
. Meeting all of the following criteria:
. Willing to maintain the same lifestyle (exercise, alcohol consumption, diet, etc.) during the study
. Voluntarily provide written consent to participate in the study

Exclusion criteria

. A subject who has past or current history of liver diseases
. A subject who has the following medical or surgical history
. A subject who has the following concomitant diseases
. A subject who has taken the following medications
. A subject who has taken IP of another study
. A subject who does not agree with appropriate methods of contraception

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Changes from baseline in results on MRI-PDFF at week12.

Timeframe: Baseline and week12

Changes from baseline in results on MRE at week12.

Timeframe: Baseline and week12

Trial details

NCT IDNCT06297434

SponsorJ2H Biotech

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-06-26

View on ClinicalTrials.gov More Non-alcoholic Steatohepatitis trials